I
Volume 68 April 1975
211
Section of Clinical Immunology & Allergy President I M Roitt MRcPath
Meeting 8 April 1974
Immunotherapy of Leukemia Professor G Mathe, Professor L Schwarzenberg, J L Amiel, P Pouillart, M Hayat, F de Vassal, C Rosenfeld and C Jasmin (Institut de Cance'rologie et d'Immunogene'tique, H6pitalPaul-Brousse, 94800- Villejuif, France)
100 %
patients submitted to immunotherapy patients without immunotherapy
New Experimental and Clinical Data on Leukiemia Immunotherapy
Until 1964, although chemotherapy has been used in many clinical trials, results were poor as far as duration of the first remission and survival were concerned. The explanation of these days failures was that chemotherapy obeys first order kinetics (Skipper et al. 1964, 1965, 1967). We Fig 1 Actuarial curves ofduration of remission of proposed to try and eradicate, by active immuno- patients treated by active immunotherapy after the end therapy, the residual leukeemic cells left alive after of chemotherapy (protocol 1). Note that time scale is chemotherapy (Mathe 1968; Mathe, Amiel et al. geometrical 1969). 100%_
Our first clinical trial was based on experiments in animals which had shown that adjuvants of systemic immunity (ASI), given alone, are 75~ < ~ 2 _ --~efficient in immunoprophylaxis, that is to say when administered before the tumour is present (Glynn et al. 1963, Old et al. 1959, Biozzi et al. SURVIVAL
Volume 68 April 1975
211
Section of Clinical Immunology & Allergy President I M Roitt MRcPath
Meeting 8 April 1974
Immunotherapy of Leukemia Professor G Mathe, Professor L Schwarzenberg, J L Amiel, P Pouillart, M Hayat, F de Vassal, C Rosenfeld and C Jasmin (Institut de Cance'rologie et d'Immunogene'tique, H6pitalPaul-Brousse, 94800- Villejuif, France)
100 %
patients submitted to immunotherapy patients without immunotherapy
New Experimental and Clinical Data on Leukiemia Immunotherapy
Until 1964, although chemotherapy has been used in many clinical trials, results were poor as far as duration of the first remission and survival were concerned. The explanation of these days failures was that chemotherapy obeys first order kinetics (Skipper et al. 1964, 1965, 1967). We Fig 1 Actuarial curves ofduration of remission of proposed to try and eradicate, by active immuno- patients treated by active immunotherapy after the end therapy, the residual leukeemic cells left alive after of chemotherapy (protocol 1). Note that time scale is chemotherapy (Mathe 1968; Mathe, Amiel et al. geometrical 1969). 100%_
Our first clinical trial was based on experiments in animals which had shown that adjuvants of systemic immunity (ASI), given alone, are 75~ < ~ 2 _ --~efficient in immunoprophylaxis, that is to say when administered before the tumour is present (Glynn et al. 1963, Old et al. 1959, Biozzi et al. SURVIVAL
